• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    11/1/22 2:10:41 PM ET
    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABMD alert in real time by email

    Gainers

    • Abiomed (NASDAQ:ABMD) shares increased by 50.3% to $378.91 during Tuesday's regular session. As of 13:30 EST, Abiomed's stock is trading at a volume of 5.0 million, which is 1802.3% of its average full-day volume over the last 100 days. The company's market cap stands at $17.2 billion. As per the news, the Q2 earnings report came out today.
    • NantHealth (NASDAQ:NH) shares moved upwards by 32.3% to $0.43. As of 13:30 EST, NantHealth's stock is trading at a volume of 175.6K, which is 270.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $49.6 million.
    • SAB Biotherapeutics (NASDAQ:SABS) stock rose 23.33% to $1.11. The market value of their outstanding shares is at $47.7 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 21.12% to $2.34. As of 13:30 EST, Sonnet BioTherapeutics's stock is trading at a volume of 82.6 million, which is 4389.5% of its average full-day volume over the last 100 days. The company's market cap stands at $10.1 million.
    • Aravive (NASDAQ:ARAV) shares moved upwards by 20.61% to $1.58. As of 13:30 EST, Aravive's stock is trading at a volume of 12.7 million, which is 5967.2% of its average full-day volume over the last 100 days. The company's market cap stands at $48.2 million.
    • Erytech Pharma (NASDAQ:ERYP) shares increased by 17.44% to $0.74. The company's market cap stands at $22.9 million.

    Losers

    • Catalent (NYSE:CTLT) shares declined by 23.2% to $50.5 during Tuesday's regular session. As of 13:30 EST, Catalent's stock is trading at a volume of 7.1 million, which is 462.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.0 billion. As per the news, the Q1 earnings report came out today.
    • Instil Bio (NASDAQ:TIL) shares declined by 22.13% to $2.57. Trading volume for this security as of 13:30 EST is 1.5 million, which is 384.3% of its average full-day volume over the last 100 days. The company's market cap stands at $333.3 million.
    • Bone Biologics (NASDAQ:BBLG) stock fell 18.45% to $0.37. Trading volume for this security as of 13:30 EST is 644.2K, which is 347.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.1 million.
    • PhaseBio Pharmaceuticals (NASDAQ:PHAS) shares decreased by 16.64% to $0.09. Trading volume for this security as of 13:30 EST is 20.3 million, which is 2055.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.2 million.
    • Acorda Therapeutics (NASDAQ:ACOR) shares decreased by 15.85% to $0.9. The current volume of 9.9 million shares is 282.4% of Acorda Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $21.9 million. As per the news, the Q3 earnings report came out today.
    • Myriad Genetics (NASDAQ:MYGN) stock fell 15.1% to $17.61. Trading volume for this security as of 13:30 EST is 549.3K, which is 111.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion. As per the news, the Q3 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABMD
    $ACOR
    $ARAV
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Instil Bio Inc.
    $TIL
    1/7/2026Buy → Neutral
    H.C. Wainwright
    Instil Bio Inc.
    $TIL
    1/6/2026$7.00Outperform → Neutral
    Robert W. Baird
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    Myriad Genetics Inc.
    $MYGN
    5/21/2025$6.00Sector Outperform → Sector Perform
    Scotiabank
    SAB Biotherapeutics Inc.
    $SABS
    5/14/2025$10.00Buy
    H.C. Wainwright
    Myriad Genetics Inc.
    $MYGN
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    Myriad Genetics Inc.
    $MYGN
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

    Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action o

    3/10/26 7:31:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

    Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142's favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutica

    3/9/26 5:16:37 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Instil Bio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Instil Bio from Buy to Neutral

    1/7/26 9:03:18 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Instil Bio from Outperform to Neutral and set a new price target of $7.00

    1/6/26 12:20:40 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/9/26 7:03:13 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief People Officer Solaiman Shereen covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 2% to 109,288 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/2/26 4:18:28 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/9/26 7:03:13 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Sullivan Eddie Joe bought $1,531 worth of shares (1,740 units at $0.88), increasing direct ownership by 0.03% to 5,232,304 units (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    12/8/23 8:00:05 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    SEC Filings

    View All

    SAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/10/26 7:35:30 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by SAB Biotherapeutics Inc.

    10-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/9/26 5:10:24 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Myriad Genetics Inc.

    EFFECT - MYRIAD GENETICS INC (0000899923) (Filer)

    3/5/26 12:15:18 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

    Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and ad

    2/23/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please reg

    2/16/26 4:15:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

    SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference. Select Preliminary Four

    1/12/26 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABMD
    $ACOR
    $ARAV
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

    11/14/24 6:59:16 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

    11/14/24 5:48:56 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care